Original-Research: Cantourage Group SE (von NuWays AG): BUY

Classification of NuWays AG to Cantourage Group SE

Company Name:	Cantourage Group SE
ISIN:	DE000A3DSV01
Reason for the research:	Update
Recommendation:	BUY
from:	14.04.2025
Target price:	EUR 13.00
Target price on sight of:	12 months
Last rating change:
Analyst:	Christian Sandherr

Growth beating expectations, again; PT up

Q1 sales surged to € 25.6m, more than quadrupling compared to the previous year's figure of € 6.1m and clearly exceeding our expectations of € 22m. Sequentially, sales grew by 21% qoq, marking a new record high. In March alone, sales stood at € 10.7m, beating the previous best month, December with € 8.5m. This increase should largely be the result of successful de-bottlenecking efforts on Cantourage’s side during the past few months. With strongly growing demand, the company has been working on raising its processing capacities at it German site as well as through partnerships (e.g. with a Portuguese contract manufacturer). Securing sufficient supply (incl. processing capacities) could allow Cantourage to reach the € 100m sales level already this year.

Scale to kick in. While Cantourage only announced sales figures, we would also expect a further improving margins as scale effects begin to kick in. We would expect an EBITDA margin of around 10% to be in the cards (for Q1) despite ongoing investments into growth.

No FY25 guidance issued yet. So far, management has not issued a guidance for the current year. We would expect a first FY25 outlook with the publication of final FY24 figures at the end of April. In light of the better than expected start into the year, unbroken demand and further de-bottlenecking efforts, we have increased our sales growth expectations from 67% to 81%, implying € 93m sales.

Easing political risks. Last week, Germany’s new government published the coalition agreement, which states an open-ended evaluation of the cannabis legalization law for autumn 2025. In our view, this is a clear positive and a return to the pre-April 1st, 2024 legal framework or a reclassification of cannabis as a narcotic now appears increasingly unlikely, not only due to the high degree of complexity as well as a wave of lawsuits but also a seemingly low importance to the new law-makers (postponed discussions and only one sentence across a 146 page document).

Share price de-coupled from fundamentals. While operations have been strongly improving quarter over quarter for roughly a year, the valuation has decreased to some € 56m. Despite expected FY25e sale growth of 81% yoy, Cantourage should be able to reach a 10% EBITDA margin, implying an attractive EV/EBITDA multiple of 5.2x.

We confirm our BUY rating with a new € 13 PT (€ 12.50) based on DCF.

You can download the research here: http://www.more-ir.de/d/32238.pdf
For additional information visit our website: https://www.nuways-ag.com/research-feed

Contact for questions:
NuWays AG - Equity Research
Web: www.nuways-ag.com
Email: research@nuways-ag.com
LinkedIn: https://www.linkedin.com/company/nuwaysag
Adresse: Mittelweg 16-17, 20148 Hamburg, Germany
++++++++++
Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben analysierten Unternehmen befinden sich in der vollständigen Analyse.
++++++++++